# Phase 1 Primary Myelofibrosis trials recruiting: 24 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in phase 1 for Primary Myelofibrosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Primary Myelofibrosis trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/primary-myelofibrosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 2, 2026 | NCT07909733 | Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT | University of Wisconsin, Madison | Phase 1 | Not yet recruiting | High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation, Acute Myeloid Leukemia (AML), Chronic Myeloid... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909733) |
| September 30, 2026 | NCT07849231 | A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms | Damora Therapeutics | Phase 1 | Recruiting | Myeloproliferative Neoplasms (MPNs) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07849231) |
| April 14, 2026 | NCT07529951 | Study of ZE74-0282 in Patients With JAK2 V617F- or Calreticulin-Mutated Hematologic Disorders | Eilean Therapeutics | Phase 1 | Recruiting | Polycythemia Vera (PV), Myelofibrosis (MF) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529951) |
| April 14, 2026 | NCT07527221 | Safety and Tolerability of ZE74-0282 in Healthy Volunteers | Eilean Therapeutics AU Pty Ltd | Phase 1 | Recruiting | Healthy Volunteers | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527221) |
| April 9, 2026 | NCT07521046 | Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis | University of Utah | Phase 1 | Recruiting | Myelofibrosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07521046) |
| March 18, 2026 | NCT07480824 | To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 | Recruiting | Myelofibrosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480824) |
| March 13, 2026 | NCT07469891 | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms | Prelude Therapeutics Incorporated | Phase 1 | Recruiting | Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469891) |
| March 2, 2026 | NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Incyte Corporation | Phase 1 | Recruiting | Myeloproliferative Neoplasms | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441694) |
| January 30, 2026 | NCT07379125 | Therapeutic RSK1 Targeting in Myeloid Malignancies | Washington University School of Medicine | Phase 1 | Recruiting | Myeloid Malignancy | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07379125) |
| December 24, 2025 | NCT07302776 | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT | Stanford University | Phase 1 | Recruiting | GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes, Myelofibrosis... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07302776) |
| November 26, 2025 | NCT07250646 | A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis | Aspera Biomedicines, Inc. | Phase 1 | Recruiting | Secondary AML, Myelofibrosis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07250646) |
| August 5, 2025 | NCT07104799 | Momelotinib During and After HCT in Myelofibrosis | Massachusetts General Hospital | Phase 1 | Recruiting | Myelofibrosis, Hematopoietic Cell Transplantation (HCT) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07104799) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| June 6, 2025 | NCT07008118 | A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Incyte Corporation | Phase 1 | Recruiting | Myeloproliferative Neoplasms | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07008118) |
| December 2, 2024 | NCT06712810 | Q702 for the Treatment of Patients With Hematologic Malignancies | Mayo Clinic | Phase 1 | Recruiting | Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06712810) |
| April 22, 2024 | NCT06378437 | A Study of GLB-001 in Patients With Myeloid Malignancies | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid... | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06378437) |
| April 3, 2024 | NCT06343805 | A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or... | Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | Phase 1 | Recruiting | Primary Myelofibrosis | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06343805) |
| January 23, 2024 | NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition | Fox Chase Cancer Center | Phase 1 | Recruiting | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Chronic... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06218628) |
| September 21, 2023 | NCT06047886 | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy | University of Alabama at Birmingham | Phase 1 | Recruiting | AML, ALL, Lymphoid Malignancies, Myelodysplastic Syndromes, CML, Primary Myelofibrosis | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06047886) |
| September 13, 2023 | NCT06034002 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative... | Incyte Corporation | Phase 1 | Recruiting | Myeloproliferative Neoplasms | 290 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06034002) |
| September 10, 2022 | NCT05535764 | AlloHCT With PegINFa for Myelofibrosis | University of Utah | Phase 1 | Recruiting | Myelofibrosis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05535764) |
| June 21, 2022 | NCT05423691 | Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | Cellenkos, Inc. | Phase 1 | Recruiting | Myelofibrosis | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05423691) |
| February 25, 2021 | NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL... | Newave Pharmaceutical Inc | Phase 1 | Recruiting | Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04771572) |
| October 31, 2017 | NCT03326310 | Selumetinib and Azacitidine in High Risk Chronic Blood Cancers | University of Chicago | Phase 1 | Recruiting | Chronic Myeloid Leukemia, Myelofibroses | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03326310) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 3 |
| University of Utah | 2 |
| Mayo Clinic | 1 |
| Cellenkos, Inc. | 1 |
| Massachusetts General Hospital | 1 |
| Eilean Therapeutics | 1 |
| Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 1 |
| Fox Chase Cancer Center | 1 |
| University of Chicago | 1 |
| Newave Pharmaceutical Inc | 1 |
| Hangzhou GluBio Pharmaceutical Co., Ltd. | 1 |
| University of Alabama at Birmingham | 1 |
| Washington University School of Medicine | 1 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 1 |
| Eilean Therapeutics AU Pty Ltd | 1 |
| Stanford University | 1 |
| University of Wisconsin, Madison | 1 |
| Damora Therapeutics | 1 |
| City of Hope Medical Center | 1 |
| Prelude Therapeutics Incorporated | 1 |
| Aspera Biomedicines, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| Australia | 6 |
| Italy | 4 |
| France | 3 |
| Spain | 3 |
| Belgium | 2 |
| Germany | 2 |
| United Kingdom | 2 |
| China | 2 |
| Uzbekistan | 1 |
| Canada | 1 |
| Japan | 1 |
| South Korea | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [Court reporters in the United States](https://specstream.ai/data/businesses/court-reporters/united-states)
- [Medical research institutes in the United States](https://specstream.ai/data/businesses/medical-research-institutes/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
